Which of the following is a clinically relevant protein produced by recombinant technology? a. insulin b. interferon c. factor VIII d. tissue plasminogen activator e. all of the above Which of the following is associated with translation efficiency for the mRNA of genes cloned for protein expression? a. mRNA stability b. strength of the ribosomal binding site c. codon usage d. mRNA secondary structure e. e. all of the above Which of the following is not a feature of translational expression vectors? a. a selectable marker (i.e., antibiotic resistance) b. terminator sequences vector c. the native promoter for the gene that is to be cloned into the vector d. consensus RBS plus the ATG initiation codon e. a strong, but regulated, transcriptional promoter